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Objective: Develop and validate particular, concrete, and abstract yet plausible in
silico mechanistic explanations for large intra- and interindividual variability observed
for eleven bioequivalence study participants. Do so in the face of considerable
uncertainty about mechanisms.
Methods: We constructed an object-oriented, discrete event model called SUBJECT
(we use small caps to distinguish computational objects from their biological
counterparts). It maps abstractly to a dissolution test system and study subject to
whom product was administered orally. A SUBJECT comprises four interconnected
grid spaces and event mechanisms that map to different physiological features and
processes. DRUGS move within and between spaces. We followed an established,
Iterative Refinement Protocol. Individualized mechanisms were made sufficiently
complicated to achieve prespecified Similarity Criteria, but no more so. Within
SUBJECTS, the DISSOLUTION space is linked to both a product-SUBJECT Interaction
Space and the GI TRACT. The GI TRACT and Interaction Space connect to PLASMA,
from which DRUG is eliminated.
Results: We discovered parameterizations that enabled the eleven SUBJECT
simulation results to achieve the most stringent Similarity Criteria. Simulated profiles
closely resembled those with normal, odd, and double peaks. We observed
important subject-by-formulation interactions within SUBJECTS.
Conclusion: We hypothesize that there were interactions within bioequivalence
study participants corresponding to the subject-by-formulation interactions within
SUBJECTS. Further progress requires methods to transition currently abstract SUBJECT
mechanisms iteratively and parsimoniously to be more physiologically realistic. As
that objective is achieved, the approach presented is expected to become beneficial
to drug development (e.g., controlled release) and to a reduction in the number of
subjects needed per study plus faster regulatory review.
Background
Large intrasubject variability in drug bioequivalence (BE) coupled with weak in vitro-
to-in vivo correlation can pose significant problems in assessing bioequivalence [1-3].
We observed examples of large intra- and interindividual variability in data from a
bioequivalence study. A proposed strategy for exploring plausible explanations, one
that has since been abandoned, was individual BE. The focus was to investigate import-
ant subject-by-formulation interactions, if they exist [4,5]. When faced with such data,© 2012 Kim et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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We used an unconventional modeling and simulation strategy to develop particular,
concrete, parsimonious yet plausible abstract answers that strove to avoid accumulating
tenuous assumptions. We present individualized answers in the form of subject-
by-formulation interactions that emerged within models for a set of eleven subjects
drawn from one BE study.
Plausible, conceptual explanations for such variability have been discussed [6].
Several pharmacokinetic modeling and simulation strategies have been offered for
deciphering atypical drug absorption profiles, including using a sum of inverse
Gaussian functions to describe absorption [7] as part of a parametric, nonlinear
mixed effects analysis [8]. Such analyses may fail because mechanisms underlying
the data contradict one or more of the assumptions on which the formal approach
rests. Sparse data aggravates the problem. That problem can be solved when popu-
lation mathematical descriptions within nonlinear mixed effect pharmacokinetic
models can be expanded to cover more mechanistic assumptions [9-11]. When data
are rich, the problem may be addressable using two-stage techniques [9], which
allow more flexibility in specifying absorption characteristics of the structural
model. However, if the failure is because different mechanisms (i.e., different struc-
tural models) seem to apply to subsets of individuals, but not on all occasions,
then multiple assumptions made by such mathematical models are violated. In that
case, even with rich data, such analyses cannot be relied upon to provide trustable
mechanistic insight. The latter situation occurs for many complex controlled release
formulations. Hénin et. al. [11] describe an example involving a complex felodipine
tablet formulation, and discusses the problem from the conventional modeling per-
spective. In such situations, different methods, like those presented herein, are
needed.
In concluding a review of methods of deciphering atypical drug absorption profiles,
Zhou [6] opined, “it can be envisioned that . . . absorption analysis may move toward
more mechanism-based rather than simply abstract number crunching. It may also be
expected that more and more novel research techniques and computational tools will
be used to greatly facilitate the in-depth understanding of absorption processes.” Such
progress would expand the “personalized medicine” vision to include complicated oral
dosage forms [10,12]. Before we can develop methods that provide exploitable explana-
tions of atypical drug absorption profiles, we need means to begin achieving deeper,
concrete insight into mechanisms that may underlie intra- and interindividual differ-
ences in bioavailability data, including subject-by-formulation interactions [5], when
they exist.
Why do we need a modeling and simulation approach that is fundamentally different
from conventional physiologically based and population pharmacokinetic approaches?
The circumstances of a BE study can be characterized by indicating an approximate lo-
cation on the two scales in Figure 1. For an established dosage form, for which we have
repeated, good correlations between in vitro measures of dissolution and bioavailability
measures, little intra-individual variability, and explainable interindividual variability,
we would select locations somewhat right of center. Being on the far right (characteris-
tic of many engineering problems) favors developing inductive models that can be pre-
cise, accurate, and predictive: the generators of underlying phenomena are well
Figure 1 Scales characterizing bioavailability studies. Any feature or property of a specific study subject
following dosing (the system) can be characterized by an approximate location on both scales. Uncertainty
example: we know very little about the likely state of the extended release dosage in a particular subject
at a particular time after dosing. Consequently, for that feature, we are left of center on the Uncertainty
Scale. Mechanistic knowledge: we know very little about the actual mechanisms responsible for differences
in drug plasma profiles. Consequently, here too, we are on the left side of the scale. We need plausible
mechanisms that can explain the large intra- and interindividual variability in bioavailability.
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isms is available at all levels of granularity. One’s location shifts left when dealing with
living systems because uncertainty increases and precise knowledge diminishes. Con-
ceptual mechanisms are less validated (thus less trustworthy) and more hypothetical.
The reliable, quantitative data that would be needed to validate (or falsify) even a mod-
estly complicated, explanatory, mechanistic model are often lacking or scarce. When
intra- and interindividual variability increases (e.g., complex, extended release formula-
tions), one’s location shifts further left, and the risks and associated problems of relying
on induction and inductive models begin accumulating. Yet the need for more compli-
cated, particular (rather than generalized) individualized explanations increases. Prior
to the introduction of object-oriented methods, there was no sound option but to con-
tinue relying on equation based, inductive models such as those used to study oral
absorption [6,13,14]. The method for doing so is straightforward and effective under
many circumstances, but hinges on an idealized scenario that enables moving far right
in Figure 1, a scenario that is easily described by an equation-based model when some
set of assumptions are met. Herein, we are not interested in idealized scenarios, so we
elected to explore the approach described below.
We began answering the question posed above by discovering plausible, abstract yet
concrete mechanistic explanations for eleven examples (exhibiting the most intra- and
interindividual variability from a study involving 32 subjects) of intra-individual differ-
ences in bioavailability and its role in the determination of BE of a generic and origin-
ator product. For reasons stated above, we sought new methods that would provide the
flexibility needed given considerable uncertainty.
We used object-oriented, discrete event, modeling and simulation methods to build
concrete software devices composed of three or more discretized spaces and mobile
objects (mapping to drug) that, when measured during simulation, mimic measured
features of drug release from a dosage form along with important features of the
plasma drug concentration versus time profiles. The device is an analogue of a subject
participating in a bioequivalence study. Hunt et al. [15] describe how the approach is
fundamentally different from conventional physiologically based and population phar-
macokinetic approaches. Our objective was to discover separate, individualized
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closely match their counterparts, as determined by prespecified Similarity Criteria (SC).
We adhered to a strong guideline: make each analogue and its mechanisms no more
complicated than needed to achieve the SC. We conjectured that once targeted SC
have been achieved for a given subject, we could hypothesize that in silico mechanistic
details might have had BE-study-subject counterparts [15] at a comparable abstraction
level. When simulation results fail to achieve the SC, we can state that the analogue
and its mechanisms do not have real world counterparts.
Starting with a simple, prototypal analogue, we used an Iterative Refinement Protocol
(IR Protocol) to improve similarity between in silico and corresponding subject plasma
profiles. We used medium and stringent, multi-attribute SC. We evaluated three struc-
turally different versions of SUBJECT, one simple and two somewhat more compli-
cated. All three achieved the medium SC for all subjects. The gastro-intestinal (GI)
component of each SUBJECT mapped to a non-homogeneous GI tract. The third
SUBJECT, the focus of this report, had a two-component, heterogeneous, individualiz-
able “GI tract.” Parameterizations were discovered that achieved the stringent SC for all
eleven plasma profile pairs. Originator and test product mean dissolution profiles were
different; a corresponding difference was built into SUBJECTS. To achieve the stringent
SC, it was necessary to specify additional, modest intra- and interindividual differences
in analogue counterparts to product dissolution. It was also necessary to specify both
intra- and interindividual differences in drug disposition within SUBJECTS.
The parameterized SUBJECTS are simple and intuitive. Coarse-grained dynamic
details can be observed during simulations. We hypothesize that all had BE study coun-
terparts. In achieving the stringent SC, SUBJECT parameterizations and executions
brought into clear focus plausible subject-by-formulation interactions. If evidence
becomes available that falsifies one or more events or processes, it is straightforward to
use the IR Protocol to make adjustments that reestablish validation. It is easy to
conceptualize mappings from events occurring during simulations and counterparts
occurring during product dissolution, drug absorption, and disposition within individ-
ual subjects. In that way, the simulations facilitate thinking more deeply about the real
system. Insights gained from this new class of simulation models may lead to ideas for
improving complicated formulations to achieve bioequivalence or enable controlled
individualization of product performance.Methods
Bioequivalence studies
A randomized, single-dose, two-way crossover study design under fasting conditions
was used to evaluate the bioequivalence of drug X in originator and test, controlled re-
lease formulations. All 32 volunteers were healthy adults. Two subjects failed to
complete the study resulting in a final N = 30, from which we selected eleven that exhib-
ited especially large or atypical variability. A validated assay (liquid chromatography -
mass spectrometry and liquid chromatography - tandem mass spectrometry) was used
to determine drug X and its metabolite levels in plasma. The assay was linear between
1 and 400 ng/ml. The overall inter-day precision (% coefficient of variation) and accur-
acy for the standards and quality control samples were within the range of 2.4 to 9.3%
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100 rpm in 900 ml of pH 7.2 buffer solutions at 37°C. Samples were taken at time 0, 0.5,
1, 1.5, 2, 4 hours and then every 2 hours thereafter to 24 hrs.In silico approach
We seek in silico mechanisms that will provide plausible, mechanistic explanations of
variability in BE. The requirements for models to be explanatory are well established
[16,17]. We constructed an object-oriented, discrete event model that maps abstractly
to two key components of a bioequivalence study: a dissolution test system and a study
subject to whom originator product and test formulation were administered orally. We
use SMALL CAPS when describing SUBJECT features and components to avoid confu-
sion and make clear that SUBJECTS cannot be the same as the BE study counterparts
to which they map. SUBJECT and its framework are illustrated in Figure 2. Because
methods that follow are different from those used for conventional pharmacokineticFigure 2 Framework. The system comprises a core, in silico model supported by framework features
for simulation and analysis. The framework simulates whole-body drug disposition experiments. The basic
design has three grid spaces that abstractly map to the dissolution compartment, GI tract, and plasma.
The arrows indicate grid-to-grid connections. DRUG objects move between the interconnected spaces,
and exit from the PLASMA grid. Simulated diffusion occurs within each grid. GI tract can be represented
using multiple grids to introduce structural and functional heterogeneity. A reservoir space is an option,
which can be added and connected to GI TRACT. Spaces shaded differently within GI TRACT indicate that
their properties can be customized, should that be needed. Supporting framework components include a
Data Processing Agent and graphical user interface. The Data Processing Agent parses parameter files and
referent data for simulation setup, and accesses SUBJECT during simulation to automatically record and
analyze measurements.
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aries are available at (http://furm.org/glossary.html) and in [15].Iterative refinement protocol
Simulation experiments must follow protocols, analogous to bioequivalence studies.
We followed the IR Protocol in Figure 3, which is based on the scientific method:
cycles of SUBJECT assembly; testing and evaluation; validation or falsification; assess-
ment; cogitation; and feature or scenario revision. The process continues until prespeci-
fied SC are achieved or not. The protocol has features in common with protocols used
for modeling and simulating complex ecological systems [18,19]. SC are discussed
below. They typically begin weak and then are strengthened, as done in [20-22]. We
used the IR Protocol successfully for different model types [20-23]. For this work, the
attributes targeted include the product dissolution profile and features of the plasma
drug level versus time profile (hereafter, simply plasma profile).
Mechanisms should be sufficiently complicated to achieve IR Protocol goals, but no
more so. There is a strong impulse to add mechanistic details (specific regions of the
intestine and flow through them, for example) before their need in achieving SC has
been demonstrated, simply because we have knowledge of those details and evidence
that they can contribute to plasma profile shape. Doing so too early is a mistake for
two reasons. 1) As explained in [15], we are not trying to build an accurate, detailed
model of typical subject. 2) It can lead to inscription error, which is the logical fallacy
of assuming the conclusion and programming in (consciously or otherwise) aspects ofFigure 3 Iterative Refinement Protocol was used to systematically develop and improve a SUBJECT
and the outcomes of in silico bioequivalence studies.
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know that we can add additional detail when needed, and doing so will be relatively
straightforward. Adhering to that parsimony guideline encourages resisting making a
SUBJECT any more complicated than needed to achieve current SC, while leaving un-
specified the many other mechanisms that might influence the plasma profile. Adhering
to that guideline is analogous to avoiding overparameteriztion of an equation-based
model. We keep framework components simple by conflating fine-grained physiologic
and anatomic details for which we have not yet demonstrated a need, and representing
them collectively using abstract objects, spaces, and/or agents having relatively simple
operating rules. Once SC and thus a degree of validation have been achieved, the beha-
viors of current components during simulation can be used for cross-model validation
during development of alternative SUBJECTS having greater mechanistic detail, as
done in [20,21,24].
When cycling through the IR Protocol, three attribute spaces are sampled and
explored: SUBJECT mechanisms (types and properties of SUBJECT components, and
their connection), parameter (including the mapping from time steps to clock time),
and phenotype (a SUBJECT’S behavior space). For this project we focused on a narrow
set of attributes, but as demonstrated in other projects [20-22,25], the focus can be a
diverse set of phenotypic attributes. For complicated phenomena like a plasma profile
during and following drug absorption, the reverse mapping from a phenomenon (e.g.,
curve shape) to plausible generators is one-to-many [15]; many, equally plausible
mechanisms (networked events) can generate any one plasma profile. When dealing
with people undergoing drug treatment, the mapping will be one-to-many no matter
how much data we have, in part because of intra- and interindividual differences. Given
ample resources, the ideal scientific strategy for gaining insight into mechanisms that
may be responsible for a given plasma profile [15] would be to sample a variety of
mechanisms and let them compete for survival through many IR Protocol cycles.
For specific mechanisms, like those depicted in Figure 2 and described below, only a
subset of all possible parameter vectors (i.e., parameter value combinations) can
achieve validation targets, in part because we are striving to be parsimonious, and
some parameter value combinations are unrealistic or abiotic. However, when the
number of attributes targeted is increased, that subset shrinks, sometimes to zero (see
[20]); in the latter case, the mechanism is falsified. However, because of framework de-
sign, when that occurs, revision is easy. Similar shrinkage occurs when SC stringency
is increased.System and SUBJECT components
We rely on object- and agent-oriented, discrete space, discrete event, software engin-
eering methods [15,26,27] coupled with relational grounding (discussed below). The
methods are analogous in several ways to established methods used for biological [28]
and ecological research [18,19]. The basic methods have been described in [20,29,30].
Instructions for conducting in silico experiments and a description of the software are
provided as Additional file 1. The following are provided in Additional file 2: a list
objects, spaces, and their referents; descriptions of system components and an architec-
ture diagram; and detailed descriptions of SUBJECT parameters.
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that map to different physiological features and processes (Figure 2). Our early, base
model had three two-dimensional (2D), toroidal grid spaces, one each mapping to dis-
solution, GI, and plasma (plus all equilibrating tissues). All grid spaces are the same
size: 100 x 100. Larger grid sizes did not measurably change SUBJECT outcome (results
not shown). At each grid location is a simple container that can hold objects or numer-
ical values. The spaces shaded differently within GI TRACT in Figure 2 illustrate that
GI TRACT’S mechanistic properties can be made heterogeneous as needed by using
multiple, independently parameterized grid spaces. The DISSOLUTION space is linked
to both the GI TRACT and an Interaction Space. We hypothesize that the Interaction
Space maps to individualized mechanistic heterogeneity that is a consequence of dosage
form–GI tract interactions. GI TRACT and Interaction Space connect separately to
PLASMA. The DISSOLUTION space and PLASMA are not connected. Not shown is
somewhat less complicated SUBJECT, in which a “reservoir” space exists in place of
Interaction Space. DRUG can move from the DISSOLUTION space to GI TRACT and
reservoir, and between GI TRACT and reservoir, but not from reservoir to PLASMA.
Framework components include a graphical user interface and data processor. The
user interface allows the user to visualize and interactively probe SUBJECT and various
parameter values during execution. The Data Processing Agent parses parameter files
and experimental data for visualization and basic analysis. The agent is also responsible
for making and recording measurements during simulation. SUBJECT and the support-
ing framework are designed to be configurable, extensible, and modular so that add-
itional, individualized components and detail can be added easily as needed.Simulating drug and its movement
Along one simulation path, drug can be represented as individual objects; along
another path, it can be represented as numerical values. We used the numerical repre-
sentation to simplify simulation and analysis. A numerical value designates the number
of mobile DRUG objects at a grid location. For the reported studies, DOSE= 10,000.
One DRUG maps to the amount of referent drug in a small aliquot of a referent fluid,
plasma for example. Related works provide examples of using individual objects to rep-
resent compounds [20,25,30,31]. An advantage of using discrete objects is that each
can carry identification information, such as a list of physicochemical properties of its
referent, as done in [31]. The object representation enables one to obtain dynamic,
fine-grained information on event histories and activities of individual DRUGS [25],
however so doing significantly increases computation costs and complexity.
Time advances discretely in time steps (also called simulation cycles). One time step
maps to several minutes; the exact number depends on other quantitative mappings, is
subject-specific, and is specified by the parameter XScale. One time step maps to 0.5 h
when XScale= 0.5. During each time step, all grid sites are updated. An update algo-
rithm computes new values for all sites in sequential order: (0, 0), (0, 1), . . .(0, n), (1, 0),
(1, 1), . . .(n, n). Once computing is complete, the update is finalized. Simulation results
are recorded at the end of each time step. That data map to snapshots of referent system
details taken at regular intervals. No assumptions are made about events occurring
between time steps.
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transfers occur between interconnected grids as illustrated in Figure 2. They are gov-
erned by a set of adjustable parameters. During each time step, a fraction of DRUG is
transferred from one grid to another. In general, when Grid A has an incoming connec-
tion from Grid B and outgoing connection to Grid C, the amount of DRUG at site (i, j)
is updated during time step t as follows:
Ai;j t þ 1ð Þ ¼ Ai;j tð Þ þ wBA fBABi;j tð Þ
  wAC fACCi;j tð Þ
  ð1Þ
where fBA specifies the fraction transferred from Grid B to A, fAC is the fraction trans-
ferred from Grid A to C, wBA and wAC are Boolean variables with parameter-controlled
probabilities. For example, DRUG transfer from GI TRACT to PLASMA is governed
by the parameters GtoPProb and GtoPFract; they specify the probability of transfer oc-
curring and the fraction of DRUG present at that site that is transferred during a time
step. For each decision, a pseudorandom number is drawn from the uniform distribu-
tion; wGP is set to ‘true’ if the drawn number <GtoPProb, otherwise ‘false’.
Intra-grid relocation simulates drug movement within (but not between) plasma, GI,
and other structures. It uses a discrete approximation algorithm: Ai;j t þ 1ð Þ ¼
Ai;j tð Þ þ d Ni;j tð Þ  Ai;j tð Þ
  
, where d is the relocation rate, t is the relocation step
counter, Ai,j(t) is the DRUG amount at grid site (i, j), and Ni,j(t) is the average DRUG
amount across grid site (i, j) and its four neighboring sites. Higher relocation rates ap-
proximate well-stirred compartments (i.e., rapid distribution). Maximum relocation
rate = 1 was used for all simulations. An iteration parameter sets the number of times
the relocation algorithm executes per time step, and that was set to 2 for all simula-
tions. Relocations execute independently of transfers.
System dynamics are a consequence of discrete events executed every time step. At
the start of simulation, the DISSOLUTION grid is initialized with DRUG DOSE distrib-
uted across that space. Within a time step, grid-to-grid transfer events execute in the
following sequence: 1) elimination from the PLASMA; 2) transfer from the GI
TRACTS to PLASMA; and 3) transfer from DISSOLUTION to GI TRACT. All other
events executed in pseudorandom order. Measurements are taken automatically every
time step and recorded to output files at the end of simulation.
Similarity criteria and quantitative comparisons
Similarity Criteria were specified arbitrarily, guided by examples of good and poor non-
linear mixed effect pharmacokinetic fits available in the literature. They are boolean
tests that determine whether or not the simulated outcome is sufficiently similar to a
feature (aspect) of the referent profile. Recent examples are provided in [25], which
compared hepatic and simulated outflow profiles of diltiazem disposition in normal
and diseased rat livers using similar, quantitative metrics. The SC specify that a simu-
lated profile be within some factor of the referent values. They define upper and lower
bounds around the target profile, and require that a specified number or ratio of simu-
lated values occur within those bounds. In this study, we expected the consequences of
a change in absorption details would be most evident in changes in ascending and des-
cending portions of disposition profiles. Consequently, when specifying similarity, we
gave more weight to those portions of the plasma profile. We specified two levels of
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ment and testing. A higher stringency SC guided further refinement so that SUBJECT
profiles matched referent more closely than did those obtained using conventional
compartmental models (Additional file 2). The medium stringency SC used the follow-
ing metrics for all nonzero values. For 0–10 h, all values must lie within a band ± 50%
of referent values; in addition, four or more values must lie within ± 20% of referent
values. For 10–48 h, all values must lie within ± 100% of referent values; in addition
three or more values must lie within ± 30%. During iterative refinement, we also modi-
fied the mean in vitro dissolution profile, within limits, when doing so was needed to
achieve plasma profile SC. The medium stringency SC for DISSOLUTION and referent
profiles required that no more than two nonzero values lie outside ± 50% of referent
values. Once we achieved the medium SC for all subjects, we applied the stringent SC,
which tightened the threshold band for plasma profiles to require all nonzero values lie
within ± 25%; in addition, four or more values must lie within ± 10% of referent values
for the 0–10 h period.
A simple quantitative comparison metric was used to assess similarity between the
simulated and subject profiles. We used the metric to guide selection of model parame-
terizations that provided for closer approximations to the referent profile. The metric
gives an average of all values computed using the following formula:
exp  y y0ð Þ=yj jð Þ ð2Þ
where y is the referent value, and y' is the simulation value. Metric values closer to 1 in-
dicate tighter approximations. The metric was applied to both the dissolution and
plasma profiles.
We used dose fraction values for comparisons described above. DOSE fraction refers
to the fraction of initial, total DRUG objects at some location within the simulation.
For example, with an initial dosage of 10,000 DRUG objects, a DOSE fraction of 0.005
translates to 50 DRUGS. We use dose fraction because it is unitless and enables direct
superposition of in silico and clinical data. It also facilitates using relational than abso-
lute grounding [32]. Comparisons were made on individual (vs. averaged) profiles; aver-
aging over multiple runs did not provide statistically meaningful or useful insights.
From simple to more complicated SUBJECTS
Adjustable delay parameters (initially DtoGDelay and GtoPDelay; later also G2toPDelay)
were needed to better approximate observed plasma profile time lags and enable
achieving the medium SC. However, when using only three grids, we failed to identify
parameterizations to achieve the stringent SC. Major confounding factors included bi-
phasic plasma profiles and the appearance of ratcheted or multiple peaks in plasma
profiles. To achieve the stringent SC, we connected a second grid space to GI TRACT
and called it reservoir; we refer to those models as R-SUBJECTS. We allowed DRUG to
move between the reservoir and GI TRACT. So doing enabled R-SUBJECTS to pro-
duce sharper and multiple peaks. It also enabled achieving the stringent SC for some
but not all subjects. Failure to achieve the stringent SC falsified that R-SUBJECT. While
reviewing failed cases, we noted that PLASMA profiles fared poorly in matching mul-
tiple peaks in the 0–15 h period. We then created new SUBJECTS having two, inde-
pendently parameterized grids (GI TRACT and Interaction Space in Figure 2) that
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match peaks. Having dual grids enabled achieving the stringent SC for all eleven
subjects. We refer to those models (Figure 2) as heterogeneous GI SUBJECTS, here-
after HGI SUBJECTS. Additional details and parameter descriptions are provided in
Additional file 2.
In addition to the parameters already specified, SUBJECTS with GI TRACT and
Interaction Space used the following parameters. DtoGFract, and DtoGProb define the
DOSE fraction transferred and the probability of transfer from DISSOLUTION grid to
both grids. DiffGRatio specifies the fraction transferred to GI TRACT and Interaction
Space; for example, when DiffGRatio= 0.8, 80% of transferred DRUG goes to GI
TRACT and 20% to Interaction Space. A difference in DiffGRatio (or another param-
eter) between the ORIGINATOR and TEST version of a SUBJECT instantiates an in
silico counterpart of a subject-by-formulation interaction.
GtoPFract, and GtoPProb govern DRUG relocation from GI TRACT to PLASMA;
G2toPFract and G2toPProb govern movement from Interaction Space to PLASMA.
PtoEDelay, PtoEFract, and PtoEProb are the probabilities controlling DRUG elimination
from PLASMA each time step. YScale is a scalar. It is applied to DOSE fraction in
PLASMA to account for differences between dissolution and plasma concentrations
measurements.Hardware and software
The framework code and instructions are available from the Corresponding Author.
SUBJECTS and supporting modules were implemented in Java using a multi-agent
simulation library, MASON (http://cs.gmu.edu/~eclab/projects/mason). Batch simula-
tion experiments were performed on a small-scale server. For model development, test-
ing, and analysis, we used personal computers. We used R 2.7 (http://www.r-project.
org) for data analysis and graph production.Results
Prior experience with this class of models provided informal heuristics for manually
searching parameter space for parameter vectors that would enable achieving the
medium SC. When cycling through the IR Protocol, we typically first adjusted para-
meters to mimic the dissolution profile. Next, we strove to mimic the plasma profile. As
indicated by how SC are specified above, we placed more emphasis on matching Cmax
and Tmax and less on matching the plasma profile tail, in part because Cmax and Tmax
are emphasized in BE studies. For each originator-test pair, we completed simulations
to first match the originator profile, and once successful, we shifted focus to matching
the test profile in new, separate simulations. With simple SUBJECTS, we discovered
parameterizations that enabled achieving the medium SC for all eleven subjects.
Having achieved the medium SC, we next focused on the stringent SC, which
required greater similarity for the 0–10 h interval. For subjects 1 and 7, we located par-
ameter vectors that enabled achieving the stringent SC for both the dissolution and
plasma profiles of the test product. However, we failed to achieve the stringent SC for
the remaining profiles, some of which exhibited noteworthy volatile patterns (e.g., sub-
jects 5 and 8). Those failures falsified the simple SUBJECT mechanisms. We shifted to
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detail, and expanded SUBJECT phenotype as reflected in plasma profiles. At that stage,
because relevant individual subject physiological details were absent, we did not get
into issues of mapping R-SUBJECT mechanisms to human reality: to do so would be
purely speculative. The increased mechanistic detail enabled achieving the stringent SC
for several additional cases (details not shown) but failed to do so for others. Again,
those failures falsified the reservoir SUBJECT mechanisms.
We then shifted attention to HGI SUBJECTS. Other strategies for increasing event
options within SUBJECTS could have been explored. Our task was simply to discover
one that could achieve the stringent SC. We did not increase model granularity (rela-
tive to R-SUBJECTS), but we did marginally increase mechanistic detail, while also
expanding SUBJECT phenotype. Again, we did not get into issues of mapping HGI
SUBJECT mechanisms to specific GI details. The increased mechanistic detail enabled
achieving the stringent SC for all cases. We located parameter vectors (Table 1) that
produced the PLASMA profiles in Figure 4 that more closely resembled the observed
profiles, and achieved the stringent SC. Having the additional Interaction Space feature
was sufficient for approximating profiles with odd peaks like those observed in subjects
5, 8, and 10. Three additional matched profiles are provided in Additional file 2.Discussion
A rationale for this new approach is that we can improve insight into the mechanisms
responsible for differences in Figure 4 plasma profiles by making the individual map-
ping from simulated to actual profile concretizable. That can only be done if the simu-
lated profiles are a consequence of actual, observable, processes. At the start of such a
process (that is where we are with this report), the actual in silico processes needed for
validation will necessarily be abstract and coarse grain.Table 1 Parameter values for HGI SUBJECTS. Order: originator/test
Subject
Parameter 1 Default 1 3 4 5 7 8 9 10
XScale 1 0.5 0.5/1.0 0.25/0.5 .125 .25/.5 .5 .125/.5 .125
YScale 120 330 220/120 120/330 220/110 110/330 110 110 110
DtoGDelay 1 1 1 1 1 1 1 1 1
DtoGFract .1 0.1/0.2 .13/.33 .05/0.2 .03/.05 .05/.16 .13/.28 .05/.25 .025/.05
DtoGProb .8 0.8 0.8 0.8 0.8 .8/.85 .8 .4/.9 .8
DiffGRatio 1 0.8/1 .65/.93 .94/.9 .75/.65 .6/1 .6/.4 .9 .88/.9
GtoPDelay 0 5/4 0 4/0 7/21 4/6 0/3 12/6 0/8
GtoPFract .1 1.0/0.3 .78/.88 .065/.14 .25/.1 .34/.46 .65/.4 .2/.38 .12/.1
GtoPProb .8 1.0/0.8 .78/.88 0.89 0.27/.3 .34/.46 .65/.4 .2/.38 .12/.1
G2toPDelay 20 32/20 18/15 19/23 96/86 39 20/21 97/26 0/58
G2toPFract .1 0.3/0.1 0.2/0.5 1.0/0.3 0.12 .13 .23/.24 .11/.23 .05/.23
G2toPProb .8 0.3/0.8 0.2/0.5 1.0/0.3 .13/.12 .13 .23/.24 .11/.23 .05/.23
PtoEDelay 0 7/0 10/3 14/7 36/0 18/11 1/11 20/0 35/48
PtoEFract 0.1 .25/.11 .14/.26 .69/.9 .125/.24 .15/.1 .14/.12 .22/.48 .11
PtoEProb 0.8 .6/.88 .8/.93 .3/.86 0.5/.4 1/.8 1/.9 .5/.4 .8
1 Additional parameter information is provided in Additional file 2.
Figure 4 Plasma profiles. Profiles for three additional subjects are provided in Additional file 2. We used
default parameter values to initialize HGI SUBJECTS and execute initial simulations. Grid size was set to
100 x 100, and probability parameters governing DRUG movement as specified in Table 1. Once initialized,
the simulation was executed and stopped after a predefined number of time steps. Simulated plasma
values were recorded each cycle and scaled in DOSE fraction to directly compare with the referent values.
If the outcome failed to satisfy the prespecified SC, we adjusted parameter values and repeated simulation.
We repeated the process for each referent profile until simulation measures achieved the SC. All simulations
with Table 1 parameter values achieved the stringent SC. Red: referent plasma profile from the BE study;
black: simulated profile from HGI SUBJECT.
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used in nonlinear mixed effects analyses hypothesizes an explanation of patterns in
plasma profile data. The mathematics describe data features predicted to arise from
conceptualized mechanisms, which in turn are typically described in sketches and prose
[1-3,6]. There is an unverifiable, conceptual mapping between equations and envisioned
mechanisms [15]. The methods used herein are different. They provide three capabil-
ities: 1) an independent, scientific means to challenge, explore, and better understand
any inductive mechanism and, importantly, the assumptions on which it rests; 2) an
additional experimental means of exploring, discovering, and testing the plausibility of
subject-by-formulation interaction details at coarse grain level, along with causes of
intra- and interindividual variability observed in bioequivalence study results; 3) a
means to leverage the investment in BE studies and the research that preceded them by
constructing and studying mechanistic analogues of dissolution and absorption pro-
cesses contemporaneously with product development.
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tic hypotheses built into that SUBJECT. An acceptable similarity between in silico and
BE study data is evidence that a concretizable mapping may exist between the dynamics
occurring during simulation and corresponding dynamics thought to occur within that
BE study subject, even though the actual events and processes in the two systems are
different. To the extent that the mapping is accepted as realistic, we can posit that the
implemented mechanisms may also have real counterparts.
However, given complex phenomena such as the profiles in Figure 4, there are, for a
prespecified level of granularity, many, equally plausible biomimetic generators. To bet-
ter understand intra- and interindividual variability, we will need to narrow the set of
competing mechanistic explanations, and zero-in on causes of subject-by-formulation
interactions, when present. To do that, we need modeling and simulation methods like
those presented herein that are intuitive, heuristic, flexible, adaptable, and easily indivi-
dualized [15,33]. Even though we present just one plausible, mechanistic explanation
for each plasma profile, it is straightforward to develop others when that is needed. An
understanding of these mechanisms may be useful in controlled-release formulation de-
velopment to minimize the type of intra-subject variation observed in Cmax for subjects
1, 2, 3, 5, 9, 10, and 11. So doing would improve in vivo absorption performance.
SUBJECTS have been designed to use relational grounding [15,32] for maximum
flexibility. For mappings to be quantitative, as in Figure 4, an additional model— a
method of scaling; a quantitative mapping— is needed to relate a SUBJECT’S PLASMA
profile directly to the referent plasma profile. That was done using the parameters
XScale and YScale. For several SUBJECTS, achieving the stringent SC required varying
the XScale and/or YScale values between the test and originator plasma profiles. XScale
maps time steps to BE study time. By changing the XScale value, we alter the time
granularity of simulation relative to in vivo time, which enables adjusting simulation for
differences in the subject’s physiological condition (as influenced by stress, for example,
or the previous day’s activities), which affect GI physiology, metabolism or other ab-
sorption and disposition related features. XScale does not influence product dissolution.
A change in YScale maps to systemic variations in plasma concentration measurements
between experiments, which may include changes in effective volume of distribution
and bioavailability. It should be noted that changes in XScale and YScale values within
or between SUBJECTS are evidence that the subject’s physiology changed between
occasions. If we were to move these scaling models into each SUBJECT, we would im-
mediately reduce SUBJECT flexibility, which is scientifically undesirable [32].
The levels of temporal, spatial, and mechanistic granularity (which control reso-
lution) are somewhat arbitrary: they need to be sufficiently fine-grain so that a SUB-
JECT’S PLASMA profile meets the stringent SC. Granularity can be easily increased
or decreased when that is needed. Because interactions within and between SUB-
JECT components are grounded relationally, an algorithm can be implemented when
needed to automatically adjust parameter values to accommodate new levels of
granularity so that the consequences of mechanisms and events can remain essen-
tially unchanged.
One might object that the SUBJECT in Figure 2 is too abstract: distinguishable GI-
like features are absent; there is no DRUG movement through sequential GI spaces,
etc. Such features are absent because they were not needed to achieve the stringent SC.
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not part of the validation strategy. However, there is a scientific approach to drill down
to additional, plausible, concrete, mechanistic detail. It requires expanding the list of
targeted attributes and using the IR Protocol in the context of cross-model validation
[24] to validate or falsify the need for that detail. Such attributes may include fine-
grained details such as distinct cell types, enzymes, and transporters (see [25] for
example). The approach is especially useful because of the scientific role played by
experimentation on the current, validated SUBJECT analogue.
Further knowledge about specific formulation and dissolution details, which we do
not have, can be used to specify additional SC that when met will shrink the space of
plausible SUBJECT mechanisms, which may bring informative details into focus. That
process may lead to identification of patient factors that correlate with subset member-
ship. The insights are expected to enable developing an improved formulation. The
SUBJECT model on which we focused represents the initial step in that direction. As
relevant findings and data from in vivo dissolution become available, we may proceed
to iteratively incorporate the information into SUBJECTS and achieve new validation.
If successful, the descendant models could provide quantitative, mechanistic, clinically
useful insight into how and why the in vitro dissolution differs (or not) from in vivo
mechanisms. That insight could guide the design and development of formulations to
optimize desired dissolution/absorption while minimizing adverse or otherwise undesir-
able characteristics.Conclusion
In summary, we used object-oriented, discrete event modeling and simulation methods
to build and individually parameterize a SUBJECT— a software device— so that when
events are measured during simulations, results mimic essential features of drug X dis-
solution profiles and individual plasma profiles measured during a BE study. In time,
the proposed methods may be beneficial to drug development (e.g., controlled release)
and to a reduction in the number of subjects needed per study plus faster regulatory re-
view. For a new molecular entity, the strategy is expected to be useful during bridging
studies (e.g., change in formulation from clinical to a new to-be-marketed version).Additional files
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